The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Abstract
The tumor suppressor p53 inhibits tumor growth primarily through its ability to induce apoptosis. Mutations in p53 occur in at least 50% of human tumors. We hypothesized that reactivation of mutant p53 in such tumors should trigger massive apoptosis and eliminate the tumor cells. To test this, we screened a library of low-molecular-weight compounds in order to identify compounds that can restore wild-type function to mutant p53. We found one compound capable of inducing apoptosis in human tumor cells through restoration of the transcriptional transactivation function to mutant p53. This molecule, named PRIMA-1, restored sequence-specific DNA binding and the active conformation to mutant p53 proteins in vitro and in living cells. PRIMA-1 rescued both DNA contact and structural p53 mutants. In vivo studies in mice revealed an antitumor effect with no apparent toxicity. This molecule may serve as a lead compound for the development of anticancer drugs targeting mutant p53.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The small molecule APR-246 (PRIMA-1Met) can reactive mutant p53 in tumor cells and trigger cell death by apoptosis.”
From Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246 (2018) · cites this paper as [6]
In the citing paper
“Given that previous studies reported that eprenetapopt induces apoptosis (5, 24), we tested the effect of eprenetapopt in a cell line model incapable of undergoing apoptosis to rule out the dependency on apoptotic machinery for eprenetapopt-induced cell death.”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [24]
In the citing paper
“our findings are contrary to reports concluding that eprenetapopt induces apoptosis through mut-p53 reactivation (5, 24) and instead supports eprenetapopt as a ferroptosis inducer (20).”
From Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction (2022) · cites this paper as [24]
In the citing paper
“Importantly, PRIMA-1 and its structural analog PRIMA-1MET (APR-246) inhibited tumor growth in mouse models of GBM [124,129,130].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [124]
In the citing paper
“As shown in Figure 5A, RITA and PRIMA-1 increased the expression of the p53 targets p21 and PUMA, based on qPCR measurements at 24 after their addition to cell cultures, similar to previous reports for other p53 mutants [36, 37].”
From Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells (2016) · cites this paper as [37]
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559 · cited 1×
“It is particularly noteworthy that PRIMA-1 can reactivate His-175 mutant p53, which has extensive structural defect”
Backgroundp53: puzzle and paradigm.Preprint
Ko, L. J., & Prives, C. L. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,346
A Matter of Life and Cell Death
Evan, G. I., & Littlewood, T. D. (1998) · Science · doi:10.1126/science.281.5381.1317 · Cited by 1,528
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S. B., McClatchey, A. I., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,468
The complexity of p53 modulation: emerging patterns from divergent signalsPreprint
Giaccia, A. J., & Kastan, M. B. (1998) · Genes & Development · doi:10.1101/gad.12.19.2973 · Cited by 1,315
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044
Regulation of the specific DNA binding function of p53
Hupp, T. R., Meek, D. W., Midgley, C., & Lane, D. P. (1992) · Cell · doi:10.1016/0092-8674(92)90562-q · Cited by 916
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 802
Tumor surveillance via the ARF–p53 pathwayPreprint
Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.19.2984 · Cited by 718
Lin, J., Chen, J., Elenbaas, B., & Levine, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.10.1235 · Cited by 652
Bullock, A. N., Henckel, J., & Fersht, A. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203434 · Cited by 440
Selivanova, G., Iotsova, V., Okan, İ., Fritsche, M., Ström, M., Groner, B., Grafström, R. C., & Wiman, K. G. (1997) · Nature Medicine · doi:10.1038/nm0697-632 · Cited by 341
Self-citationActivation of the cryptic DNA binding function of mutant forms of p53
Hupp, T. R., Meek, D. W., Midgley, C., & Lane, D. P. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.14.3167 · Cited by 190
p53 gene mutation: software and database
Béroud, C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.147 · Cited by 185
Mechanism of rescue of common p53 cancer mutations by second‐site suppressor mutations
Nikolova, P. V., Wong, K., DeDecker, B. S., Henckel, J., & Fersht, A. R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.3.370 · Cited by 173
Brachmann, R. K., Yu, K., Eby, Y. J., Pavletich, N. P., & Boeke, J. D. (1998) · The EMBO Journal · doi:10.1093/emboj/17.7.1847 · Cited by 157
p53 gene mutation: software and database
Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.200 · Cited by 149
Reactivation of Mutant p53 through Interaction of a C-Terminal Peptide with the Core Domain
Selivanova, G., Ryabchenko, L. G., Jansson, E. Å., Iotsova, V., & Wiman, K. G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3395 · Cited by 139
Self-citationKim, A. L., Raffo, A. J., Brandt‐Rauf, P. W., Pincus, M. R., Monaco, R. R., Abarzúa, P., & Fine, R. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34924 · Cited by 114
Hansen, S., Hupp, T. R., & Lane, D. P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3917 · Cited by 96
Regulation of Mutant p53 Temperature-sensitive DNA Binding
Friedlander, P. A., Legros, Y., Soussi, T., & Prives, C. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.41.25468 · Cited by 94
Identification of an additional negative regulatory region for p53 sequence-specific DNA binding
Müller‐Tiemann, B., Halazonetis, T. D., & Elting, J. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6079 · Cited by 89
Structure–based rescue of common tumor–derived p53 mutants
Wieczorek, A. M., Waterman, J. L. F., Waterman, M. J. F., & Halazonetis, T. D. (1996) · Nature Medicine · doi:10.1038/nm1096-1143 · Cited by 88
Abarzúa, P., LoSardo, J. E., Gubler, M. L., & Neri, A. (1995) · PubMed · Cited by 83
p53-Induced Apoptosis as a Safeguard against Cancer
Asker, C., Wiman, K. G., & Selivanova, G. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1446 · Cited by 79
Self-citationImmunolocalization of Human p14ARF to the Granular Component of the Interphase Nucleolus
Lindström, M. S., Klangby, U., Inoue, R., Pisa, P., Wiman, K. G., & Asker, C. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4854 · Cited by 77
Self-citationMutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240.
Wiman, K. G., Magnússon, K. P., Ramqvist, T., & Klein, G. (1991) · PubMed · Cited by 70
Self-citationThe single-stranded DNA end binding site of p53 coincides with the C- terminal regulatory region
Selivanova, G. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.18.3560 · Cited by 65
Self-citationReactivation of mutant p53: a new strategy for cancer therapy
Selivanova, G., Kawasaki, T., Ryabchenko, L. G., & Wiman, K. G. (1998) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0099 · Cited by 63
Self-citationCohen, P. A., Hupp, T. R., Lane, D. P., & Daniels, D. A. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01603-8 · Cited by 13
Functional Rescue of Mutant p53 as a Strategy to Combat Cancer
Selivanova, G., & Wiman, K. G. (2002) · Elsevier eBooks · doi:10.1016/b978-012476249-7/50021-7 · Cited by 3
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,351
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Metadata
- Authors
- Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G.
- Affiliations
- Karolinska University Hospital (SE)
- Engelhardt Institute of Molecular Biology (RU)
- Karolinska Institutet (SE)
- Corresponding author
- Wiman, Klas G.
- ORCID
- Venue
- Nature Medicine
- Published
- 2002-03
- Volume
- 8
- Issue
- 3
- Pages
- 282-288
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2092902276
- Cited by
- 1,067
- References
- 32
- Citations by year
- 2026: 22 · 2025: 29 · 2024: 42 · 2023: 51 · 2022: 49 · 2021: 58 · 2020: 55 · 2019: 53 · 2018: 51 · 2017: 34 · 2016: 53 · 2015: 42 · 2014: 51 · 2013: 38 · 2012: 37
- FWCI
- 18.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- mutant p53, PRIMA-1, p53 reactivation, tumor suppressor function, apoptosis, transcriptional activation, small molecules, anticancer drug development, DNA binding, p53 conformation, anticancer activity
- MeSH terms
- Animals, Antineoplastic Agents, Aza Compounds, Cell Separation, Flow Cytometry, Humans, Molecular Weight, Mutation, Neoplasms, Organic Chemicals, Protein Conformation, Transplantation, Heterologous, Tumor Cells, Cultured, Molecular Structure, Transcriptional Activation, Tumor Suppressor Protein p53, Apoptosis, Genes, Reporter, Bridged Bicyclo Compounds, Heterocyclic, In Situ Nick-End Labeling, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
